
Nivolumab produces durable responses & long-term survival in severe liver cancer patients
Results from the CheckMate 040 study found that nivolumab, an immuno-oncology drug which acts by…
Results from the CheckMate 040 study found that nivolumab, an immuno-oncology drug which acts by…